Sponsor Responsibilities— Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies

Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <u>https://www.regulations.gov</u>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (CDER) Paul Gouge, 301-796-2500, or (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-8010.

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)

> June 2021 Drug Safety

Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies

Guidance for Industry

Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: druginfo@fda.hhs.gov https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

and/or

Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: ocod@fda.hhs.gov https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)

> > June 2021 Drug Safety

Draft — Not for Implementation

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	2
III.	DEFINITIONS (§ 312.32(a))	3
А.	Adverse Event (§ 312.32(a))	3
В.	Adverse Reaction and Suspected Adverse Reaction (§ 312.32(a))	3
C.	Unexpected (§ 312.32(a))	5
D.	Serious (§ 312.32(a))	6
Е.	Life-Threatening (§ 312.32(a))	7
IV.	OVERVIEW OF IND SAFETY REPORTING REQUIREMENTS	7
А.	Serious and Unexpected Suspected Adverse Reaction (§ 312.32(c)(1)(i))	8
	Events That Do Not Require Aggregate Analyses Events That Require Aggregate Analyses IND Safety Reporting Criteria for Aggregate Data	.11
	Serious and Unexpected Suspected Adverse Reactions (§ 312.32(c)(1)(i)(C)) Increased Rate of Occurrence of Serious Suspected Adverse Reactions (§ 312.32(c)(1)(iv)) Other Reporting Requirements	. 13
2. V.	Findings from Other Sources (§ 312.32(c)(1)(ii) and (iii)) IND Safety Reports for Study Endpoints (§ 312.32(c)(5)) SYSTEMATIC APPROACH FOR REVIEW OF SAFETY INFORMATION .32(b))	. 14
А.	Prospective Development of a Plan for Safety Surveillance	.16
VI. REPO	CONSIDERATIONS FOR AGGREGATE DATA ANALYSIS FOR IND SAFET ORTING	Y
А.	Identify Serious Adverse Events Anticipated to Occur in the Study Population	.18
В.	Aggregate Analyses of Safety Data	.18
2.	Approach to Aggregate Analyses Frequency of Aggregate Analyses Considerations When Evaluating Aggregate Data Entities That Review Aggregate Data for IND Safety Reporting	.20 .20
	Features and Composition of the Entity Identifying the Entities that Review Safety Information Maintaining Trial Integrity When Reviewing Aggregate Data	. 21
VII.	OTHER SAFETY REPORTING ISSUES	. 23
А.	Alternative Reporting Arrangements (§ 312.32(c)(3))	23
B.	Importance of Standardized Coding	

Draft — Not for Implementation

C.	Investigations of Marketed Drugs (§ 312.32(c)(4))	.24
D.	Duration of Safety Reporting	.25
VIII.	SUBMITTING AN IND SAFETY REPORT (§ 312.32 (c)(1)(v))	25
А.	Report Identification and Format	.25
	Individual Cases Reports of Events Identified by Aggregate Analyses	
	Other Reports	. 28
C.	Reporting Time Frame	.29
IX.	FOLLOW-UP INFORMATION (§ 312.32(d))	30
X.	SAFETY REPORTING REQUIREMENTS FOR BA AND BE STUDIES	31
А.	BA/BE Study Safety Reporting Requirements (§ 320.31(d)(3))	.32
B.	How and Where to Submit a Report (§ 320.31(d)(3))	.32
REFE	RENCES	35
EVEN	NDIX A: FLOWCHART FOR DETERMINING WHETHER AN ADVERSE T MEETS CRITERIA FOR IND SAFETY REPORTING TO FDA AND STIGATORS	37
	NDIX B: FLOWCHARTS FOR SUBMITTING SAFETY REPORTING FOR TROL DRUGS	38
Cha	rt B.1: IND Sponsor is <i>NOT</i> the NDA or BLA Holder of the Control Drug	.38
Cha	rt B.2: IND Sponsor <i>IS</i> also the NDA or BLA Holder of the Control Drug	.39
	NDIX C: FLOWCHART FOR THE TWO APPROACHES TO AGGREGATE YSES	40

Draft — Not for Implementation

Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies Guidance for Industry¹

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

13

1

2

3

8

9

10

11

12

14 15

16 I. INTRODUCTION 17

18 This guidance provides recommendations to help sponsors comply with the expedited safety

19 reporting requirements for human drug and biological products² that are being investigated (1)

20 under an investigational new drug application (IND) (21 CFR 312.32) or (2) as part of a

21 bioavailability (BA) or bioequivalence (BE) study that is exempt from the IND requirements (21

22 CFR 312.64(b) and 320.31(d)(3)). 23

24 This guidance defines terms used for safety reporting, makes recommendations on when and

how to submit a safety report, and provides information on other safety reporting issues raised by
 sponsors.

27

28 To facilitate appropriate IND safety reporting practices, this guidance also provides

recommendations related to the two IND safety reporting provisions (21 CFR 312.32(c)(1)(i)(C)and 312.32(c)(1)(iv)) that require assessment of aggregate data.

31

32 This guidance merges content from the final guidance for industry and investigators Safety

33 *Reporting Requirements for INDs and BA/BE Studies* (December 2012) (the 2012 final

34 guidance) and from the draft guidance for industry Safety Assessment for IND Safety Reporting

35 (December 2015) (the 2015 draft guidance).³ This guidance includes revised recommendations

36 initially described in the 2015 draft guidance on the following topics: (1) planned unblinding of

¹ This guidance has been prepared by the Office of Medical Policy in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA).

 $^{^{2}}$ This guidance applies to drugs, including biological products. For the purposes of this guidance, *drug* or *drug product* is used to refer to human drugs and human biological products that are regulated as drugs.

³ We update guidances periodically. For the most recent version of a guidance, check the FDA guidance web page at <u>https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.</u>

Draft — Not for Implementation

safety data and implications for trial integrity; (2) increased flexibility regarding the party 37

38 reviewing aggregate safety information for IND safety reporting purposes; (3) clarification

39 regarding the scope and methodology of aggregate analyses; and (4) clarification regarding the

40 plan for safety surveillance, including what elements should be included in the plan. The 2015

41 draft guidance has been withdrawn upon the publication of this guidance.

42

43 The content from the 2012 final guidance remains largely unchanged in this draft guidance.

44 When finalized, this guidance will supersede the 2012 final guidance. However, until that time,

45 the 2012 final guidance continues to represent FDA's current thinking about safety reporting

requirements for INDs and BA/BE studies. This guidance does not incorporate content on 46 47 investigator reporting (21 CFR 312.64(b)) from the 2012 final guidance. FDA plans to publish a

48 separate draft guidance for clinical investigators on investigators' responsibilities for safety

49 reporting for human drug and biological products. However, until that draft guidance is

50 finalized, the 2012 final guidance continues to represent FDA's current thinking about

51 investigators' responsibilities for safety reporting for INDs and BA/BE studies.

52

53 This guidance addresses reporting of serious adverse events (SAEs) in the setting of a clinical

54 investigation conducted under an IND. Drugs used in such clinical investigations may be

55 unapproved drugs or those that are already marketed or approved in the United States. For drugs

56 already marketed or approved, additional reporting requirements for safety information from

57 clinical studies are specified by the relevant postmarketing safety reporting requirements (e.g.,

58 under 21 CFR 314.80, 600.80, or 606.170 or under section 760 of the Federal Food, Drug, and

59 Cosmetic Act (FD&C Act) (21 U.S.C. 379aa); see also § 312.32(c)(4)). This guidance does not 60

61

address those obligations.

62 The contents of this document do not have the force and effect of law and are not meant to bind 63 the public in any way, unless specifically incorporated into a contract. This document is intended 64 only to provide clarity to the public regarding existing requirements under the law. FDA

65 guidance documents, including this guidance, should be viewed only as recommendations, unless 66 specific regulatory or statutory requirements are cited. The use of the word *should* in FDA 67 guidances means that something is suggested or recommended, but not required.

68 69

70 II. BACKGROUND

71

72 On September 29, 2010, FDA published a final rule (75 FR 59935) amending IND safety 73 reporting requirements under 21 CFR part 312 and adding safety reporting requirements for

74 persons conducting BA and BE studies under 21 CFR part 320. The IND safety reporting 75 regulations distinguish between circumstances in which it is appropriate to submit IND safety

76 reports based on individual cases (§ 312.32(c)(1)(i)(A) and (B)) and circumstances in which an

77 IND safety report would need to be based on an aggregate analysis of SAEs to determine

78 whether the events occur more frequently in the drug treatment group (\S 312.32(c)(1)(i)(C)).

79 Compliance with these requirements increases the likelihood that submitted information will be

80 interpretable and will meaningfully contribute to the developing safety profile of the

81 investigational drug and improve the overall quality of safety reporting.

Draft — Not for Implementation

Timely reporting of the required safety information allows FDA to consider whether any changes 83 84 in study conduct should be made beyond those initiated by the sponsor and allows investigators to make any changes that are needed to protect subjects. An effective systematic approach by 85 sponsors to safety surveillance, coupled with limiting the scope of IND safety reports to FDA 86 87 and participating investigators (and subsequent reporting to involved institutional review boards) 88 to **suspected adverse reactions that are both serious and unexpected**, allows all parties to 89 focus on important safety issues and take actions needed to minimize the risks of participation in 90 a clinical trial.⁴ 91 92 The 2010 final rule also requires sponsors to report findings from other studies (§ 93 312.32(c)(1)(ii) and findings from animal⁵ or in vitro testing (§ 312.32(c)(1)(iii)) that suggest a 94 significant risk to humans exposed to the drug and to report an increased occurrence of known 95 serious suspected adverse reactions (§ 312.32(c)(1)(iv)). 96 97 98 III. **DEFINITIONS** (§ 312.32(a)) 99 100 A. Adverse Event (§ 312.32(a)) 101 102 Adverse event means "any untoward medical occurrence associated with the use of a drug in 103 humans, whether or not considered drug related" (§ 312.32(a)). 104 105 FDA considers an *adverse event* (also referred to as an *adverse experience*) to include any 106 unfavorable sign (e.g., an abnormal laboratory finding), symptom, or clinical outcome 107 temporally associated with the use of a test drug, active control, or placebo, regardless of 108 whether the event is thought to be related to the drug. An adverse event can arise during any use 109 of a drug or biologic (e.g., use for a purpose other than the FDA-approved indication or in 110 combination with another drug) and with any route of administration, formulation, or dose, 111 including an overdose. 112 113 B. Adverse Reaction⁶ and Suspected Adverse Reaction (§ 312.32(a)) 114 115 An adverse reaction means any adverse event caused by a drug. Suspected adverse reaction

116 means "any adverse event for which there is a *reasonable possibility* that the drug caused the

adverse event. For the purposes of IND safety reporting, *reasonable possibility* means there

⁴ In most cases such events will lead to an update to the investigator brochure and/or informed consent.

⁵ We support the principles of the "3Rs," to reduce, refine, and replace animal use in testing when feasible. We encourage sponsors to consult with us if they wish to use a non-animal testing method they believe is suitable, adequate, validated, and feasible. We will consider if such an alternative method could be assessed for equivalency to an animal test method.

⁶ For the purposes of prescription drug labeling, the term *adverse reaction* is defined to mean "an undesirable effect, reasonably associated with use of a drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence." "This definition does not include all adverse events observed during use of a drug, only those adverse events for which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event" (see 21 CFR 201.57(c)(7) and 201.80(g)).

Draft — Not for Implementation

118 119 120 121 122 123	is evidence to suggest a causal relationship between the drug and the adverse event. Suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction[.]" Both an adverse reaction and a suspected adverse reaction require evidence of a causal relationship between the drug and the adverse event. Therefore, if no drug has been administered, an adverse event is not reportable under IND safety reporting regulations. ⁷
124 125 126	The following examples provided in the IND safety reporting regulation (§ 312.32(c)(1)(i)) illustrate the meaning of <i>reasonable possibility</i> with respect to a determination that there may be a causal relationship between the drug and the adverse event:
127 128 129 130	• A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome).
131 132 133	• One or more occurrences of an event that is not commonly associated with drug exposure but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture).
134 135 136 137 138 139	• An aggregate analysis of specific events observed in a clinical trial, indicating that they occur more frequently in the drug treatment group than in a concurrent or historical control group. Such events may be known consequences of the underlying disease or condition or events that commonly occur in the study population independent of drug therapy. Such events could also be related to an intervention or therapy that is standard of care for the disease (e.g., background treatment).
140 141 142 143 144 145	To determine whether an adverse event should be classified as a <i>suspected adverse reaction</i> , or an adverse reaction, the sponsor must evaluate the available evidence (§ 312.32(b)) and make a judgment about the likelihood that the drug caused the adverse event. For an adverse event to be considered a suspected adverse reaction, the sponsor should conclude that there is a reasonable possibility that the drug caused the adverse event. FDA considers the application of the
146 147 148	<i>reasonable possibility</i> causality standard to be consistent with the discussion about causality in the International Council for Harmonisation (ICH) E2A guideline for industry (the ICH E2A guidance). ⁸ However, FDA notes there is a difference between the IND safety reporting rule and
149 150 151 152	the ICH E2A guidance with respect to who is responsible for making the causality judgment for reporting purposes. The sponsor is responsible for making the causality judgment, according to the IND safety reporting rule; in contrast, the ICH E2A guidance recommends that the judgment
152 153	for reporting be based on either the investigator's or the sponsor's opinion. This difference is addressed in section IV.A of this guidance.

⁷ However, for clinical investigations that involve an invasive procedure that would not occur other than due to participation in the trial (e.g., intrahepatic artery administration or a kidney biopsy), FDA may request that sponsors also report SAEs associated with such a procedure, even if the investigational product is not administered.

⁸ ICH guidance for industry *E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting* (March 1995), pages 6–7.

Draft — Not for Implementation

155 **C**. **Unexpected** (§ 312.32(a)) 156 An adverse event or suspected adverse reaction is considered *unexpected* if (1) it is not listed in 157 the investigator's brochure⁹ or it is not listed at the specificity or severity that has been observed 158 159 in the study population; or (2) if an investigator brochure is not required or available, it is not 160 consistent with the risk information described in the general investigational plan or elsewhere in 161 the application. For example, if the listed term in the investigator's brochure is erythema, a 162 reported event of Stevens-Johnson Syndrome is both more specific and more severe than the 163 term in the investigator's brochure and would therefore be considered unexpected. In addition, if 164 the event occurs at a rate that is meaningfully higher than listed in the investigator's brochure, 165 that rate would be considered to make the event more specific or severe than that listed in the 166 investigator's brochure, and it would also be considered unexpected. If there is no investigator's 167 brochure, an unexpected adverse reaction is one that is not consistent with the risk information described in the general investigational plan or elsewhere in the current IND, as amended. For 168 169 reporting purposes, events should be listed in the investigator's brochure if they have been 170 observed with the particular drug under investigation and for which a causal relationship with the 171 drug is suspected or confirmed.¹⁰ 172 173 When new adverse event information is received, it is the sponsor's responsibility to determine 174 whether the event is *unexpected* for IND safety reporting purposes. 175 176 For example, under this definition of *unexpected*, if the investigator's brochure referred only to 177 elevated hepatic enzymes or hepatitis, an event of hepatic necrosis would be unexpected (by 178 virtue of greater severity). Similarly, intracerebral hemorrhage and cerebral vasculitis would be 179 unexpected (by virtue of greater specificity) if the investigator's brochure only listed cerebral 180 vascular accidents. Unexpected also refers to adverse events or suspected adverse reactions that 181 are mentioned in the investigator's brochure as occurring with a class of drugs or as predicted to 182 occur from the pharmacological properties of the drug but are not specifically mentioned as occurring with the particular drug under investigation. For example, although angioedema is 183 184 known to occur in some individuals exposed to drugs in the angiotensin-converting enzyme 185 (ACE) inhibitor class and therefore would be described in the investigator's brochure as a class 186 effect, a case of angioedema observed with the drug under investigation should be considered 187 *unexpected* for reporting purposes until angioedema is included in the investigator's brochure as occurring with the drug under investigation. Likewise, safety-related findings from animal 188 189 studies that have not been observed with the drug under investigation in humans would also be 190 considered unexpected until such an event occurs in humans and is listed in the investigator's 191 brochure as a known or suspected adverse reaction.

- 192
- 193 There has been some confusion about the terms *expected* and *anticipated* as used for the
- 194 purposes of IND safety reporting. The terms have distinct meanings. *Expected* refers to known
- 195 or suspected adverse reactions to the drug, as listed in the investigator's brochure or, if an

⁹ For an FDA approved drug, an unexpected adverse event would include adverse events not listed in the FDAapproved labeling.

¹⁰ The investigator's brochure should not list adverse events that are unlikely to have been caused by the drug, because such lists could dilute clinically meaningful risk information.

Draft — Not for Implementation

196 investigator brochure is not required or available, as consistent with the risk information 197 described in the general investigational plan or elsewhere in the IND. Anticipated refers to 198 adverse events that are likely to occur in the study population because the adverse events (1) 199 reflect consequences of participants' underlying disease or factors such as age and (2) are 200 unrelated to an effect of a drug (e.g., cancer-related deaths in a cancer trial, strokes or acute 201 myocardial infarctions in an older population). Thus, as stated above, events that are listed in the 202 investigator's brochure are considered *expected* adverse reactions for the drug because they are 203 thought to be caused by the drug. However, the term *expected* has also been incorrectly used to 204 describe adverse events that are *anticipated* in individuals with the disease being treated or 205 population being studied but are not listed in the investigator's brochure as known or suspected 206 adverse reactions. For reporting purposes, events that are *anticipated* for the disease being 207 treated or the population being studied are considered *unexpected* because the events are not 208 listed in the investigator's brochure (i.e., the test drug is not suspected or known to cause the 209 events).

210

211 To summarize, an adverse event that is *anticipated* in the population being studied refers to an

event that would be seen in this population *independent of study drug exposure*. An *expected*

213 *adverse reaction* refers to an adverse event that is known or suspected to be *caused by the study*

214 *drug* and should be listed in the description of the known or suspected adverse drug reactions in

215 the investigator's brochure or, if an investigator brochure is not required or available, as

- 216 consistent with the risk information described in the general investigational plan or elsewhere in 217 the IND.
- 217

227

228

Because anticipated adverse events occur in the study population, the observations of a single event or a small number of such adverse events will generally not meet the criteria for being a suspected adverse reaction. To conclude that the drug may have caused an anticipated adverse event, one would perform an unblinded aggregate analysis to compare the rates in the treatment and comparator groups. The decision as to whether unblinding of an ongoing trial is appropriate to make such an assessment is discussed in section VI of this guidance. Monitoring and reporting anticipated adverse events are further discussed in section IV.

D. Serious (§ 312.32(a))

229 An adverse event, adverse reaction or suspected adverse reaction is considered *serious* "if, in the 230 view of either the investigator or the sponsor, it results in any of the following: death, a life-231 threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a 232 persistent or significant incapacity or substantial disruption of the ability to conduct normal life 233 functions, or a congenital anomaly/birth defect. Important medical events that might not result in 234 death, are not life-threatening, and do not require hospitalization may be considered serious 235 when, based upon appropriate medical judgment, they may jeopardize the patient or subject and 236 may require medical or surgical intervention to prevent one of the outcomes listed in this 237 definition. Examples of such medical events include allergic bronchospasm requiring intensive 238 treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in 239 inpatient hospitalization, and the development of drug dependency or abuse." 240

Draft — Not for Implementation

The sponsor and the investigator must evaluate whether an event meets the definition of *serious*. See §§ 312.32(c)(1)(i) and 312.64(b). Because identifying SAEs is critically important for the evaluation of potential significant safety problems, FDA considers it important to take into account both the investigator's and the sponsor's assessments. Therefore, if the sponsor or investigator believes that the event is serious, the event must be considered serious and must be evaluated by the sponsor for expedited reporting (§§ 312.32(a) and 312.32(c)(1)).

247 248

E. Life-Threatening (§ 312.32(a))

An adverse event or suspected adverse reaction is considered *life-threatening* "if, in the view of either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, might have caused death." For example, not all seizures are considered lifethreatening, although the most severe form, status epilepticus, is a life-threatening medical emergency.

As with the definition of *serious*, the determination of whether an adverse event is life-

threatening can be based on the opinion of either the investigator or sponsor. Thus, if *either* believes that the adverse event meets the definition of life-threatening, it must be considered lifethreatening for reporting purposes (§ 312.32(a)).

- 261
- 262
- 263

IV. OVERVIEW OF IND SAFETY REPORTING REQUIREMENTS

264

265 Under § 312.32(c), the sponsor is required to notify FDA and all participating investigators 266 through an IND safety report (i.e., 7- or 15-day expedited report) of potentially serious risks from 267 clinical trials or any other source as soon as possible but no later than 15 calendar days after the 268 sponsor receives the safety information and determines that the information gualifies for reporting in an IND safety report (see section VIII.C of this guidance for a discussion of IND 269 270 safety reporting time frames). Participating investigators include all investigators, at U.S. and 271 non-U.S. sites, to whom the sponsor is providing the drug under any of its INDs or under any investigator's IND (§ 312.32(c)(1)).¹¹ See Appendix A for a flowchart to help determine 272 273 whether an adverse event meets the criteria for IND safety reporting to FDA. 274

The sponsor must identify in each IND safety report all IND safety reports previously submitted to FDA concerning a similar suspected adverse reaction and must analyze the significance of the suspected adverse reaction in light of previous, similar reports or any other relevant information (i.e., conduct an analysis of similar events) (§ 312.32(c)(1)). The analysis must include similar IND safety reports from all INDs for the same drug held by the sponsor, any other relevant information known to the sponsor (§ 312.32(c)(1)), and should include related reports or adverse events available from pre- and postmarketing studies.

²⁸²

¹¹ Although not required by regulations, FDA recommends that sponsors notify investigators at non-IND sites of information meeting IND safety reporting criteria in a similar time frame as required for IND safety reports to protect subject safety.

Draft — Not for Implementation

283 Sponsor-investigators, as defined in § 312.3(b), are required to comply with both the sponsor and 284 the investigator responsibilities under part 312. FDA recognizes that a sponsor-investigator may 285 not have access to complete safety data maintained by a commercial sponsor or other sponsor-286 investigators, but sponsor-investigators are responsible for evaluating all safety information 287 available to them, including data from reports in the scientific literature and reports from foreign 288 commercial marketing experience, if known. See § 312.32(b). To protect human subjects, FDA 289 recommends that entities that provide a drug to or receive a drug from other entities share safety 290 information with each other.

291 292

A. Serious and Unexpected Suspected Adverse Reaction (§ 312.32(c)(1)(i))

293 294 The sponsor must report in an IND safety report any suspected adverse reaction to study 295 treatment (including active comparators) that is both serious and unexpected (§ 296 312.32(c)(1)(i)).¹² Before submitting an IND safety report, the sponsor needs to ensure that the 297 event meets three criteria: (1) it is serious; (2) it is unexpected (i.e., not listed in the 298 investigator's brochure or is not listed at the specificity or severity that has been observed), or, if 299 an investigator brochure is not required or available, is not consistent with the risk information 300 described in the general investigational plan or elsewhere in the IND; and (3) there is evidence to 301 suggest a causal relationship between the drug and the adverse event (i.e., it is a suspected 302 adverse reaction). If the adverse event does not meet all three criteria, it should not be 303 submitted as an IND safety report.¹³

304

Deciding whether the SAE meets the definition of a *suspected adverse reaction* is usually the most difficult determination, but this decision is critical to avoiding the submission of uninformative IND safety reports. Once the adverse event is determined to be serious and unexpected, the *sponsor* should evaluate the available information and decide whether there is a reasonable possibility that the drug caused the adverse event and, therefore, that the event also meets the definition of a *suspected adverse reaction*. Serious and unexpected suspected adverse reactions must be reported in an IND safety report (§ 312.32(c)(1)(i)).

312

313 Under § 312.64(b), investigators are required to provide a causality assessment for each SAE

314 reported to the sponsor. The sponsor should consider the investigator's assessment but must

315 submit an IND safety report *only* for those events for which the *sponsor* determines there is a

reasonable possibility that the drug caused the event ($\frac{312.32(c)(1)(i)}{1000}$). Thus:

¹² The sponsor must submit an IND safety report for any suspected adverse reaction to study treatment that is both serious and unexpected, including suspected adverse reactions to active comparators that are marketed or approved in the United States. Postmarketing safety reporting requirements (§§ 314.80 and 600.80) apply to the NDA or BLA holder but not to the IND sponsor. As a result, unless the IND sponsor and NDA/BLA holder are the same, or the NDA/BLA holder becomes aware of the suspected adverse reaction, these reactions would not be submitted as a postmarketing 15-day Alert Report. Requiring sponsors to report all suspected adverse reactions that meet the standard for reporting, even those that occur with the control drug, in IND safety reports will minimize the risk that suspected adverse reactions will not be reported to FDA. Such reporting is essential for participant safety.

¹³ Adverse events that do not meet the criteria for reporting in an IND safety report must still be reported in accordance with the periodic reporting regulations, when applicable (e.g., § 312.33 IND annual report).

Draft — Not for Implementation

	Draft — Not for Implementation
318 319 320	• The sponsor <i>should not</i> report events for which the investigator's assessment is positive for causality but the sponsor's evaluation did not find evidence to suggest a causal relationship between the drug and the event.
321	
322	• The sponsor <i>must</i> report events for which the investigator's assessment is negative for
323	causality but the sponsor's evaluation found evidence to suggest a causal relationship
324	between the drug and the event ($\frac{312.32(c)(1)(i)}{1000000000000000000000000000000000000$
325	
326	The investigator's assessment of causality must be included in the report submitted to the
327	sponsor. See § 312.64(b). If the investigator fails to provide a causality assessment or assesses
328	the causality as unknown, the sponsor will need to evaluate the event without the investigator's
329	assessment. See § 312.32(b) and (c).
330	
331	Serious and unexpected suspected adverse reactions reported in an IND safety report can be
332	divided into four categories depending on the type of event. As discussed below in section
333	IV.A.1.a and b, the first two categories (§ 312.32(c)(1)(i)(A) and (B)) can generally be assessed
334	on the basis of an individual or a small number of events. Aggregate analyses are needed for (1)
335	anticipated adverse events for which it is difficult or impossible to make a causal determination
336	based on a single case or a small number of cases and where an aggregate analysis comparing the
337	rate of such events in the intervention arm compared to a control is needed (see
338	§ 312.32(c)(1)(i)(C)); or (2) adverse or suspected adverse reactions that must be reported if the
339	incidence is higher than described in the protocol or investigator's brochure (§ 312.32(c)(1)(iv))
340	and therefore for which an aggregate analysis comparing the rate of the adverse or suspected
341	adverse reaction in the study to past rates is needed.
342	
343	If the study under an IND has an active control group but the sponsor is not the new drug
344	application (NDA) or biologics license application (BLA) holder for the control drug, serious
345	and unexpected adverse events in the control group that can be assessed as suspected adverse
346	reactions based on an individual or small number of events must be reported as individual events
347	as described in § 312.32(c)(1)(i)(A) and (B). If the sponsor is also the NDA or BLA holder for
348	the control drug, the serious and unexpected suspected adverse reaction must also be submitted
349	as required under postmarketing regulations. See § 312.32(c)(4). (See flowcharts in
350	Appendix B.)
351	
352	During an aggregate analysis to determine whether there is an increase in serious anticipated
353	adverse events in the group receiving the investigational drug that would need to be reported
354	under § $312.32(c)(1)(i)(C)$, a sponsor who is not the NDA or BLA holder for the control drug
355	may discover that the rate of the anticipated adverse event is higher in the control arm than in the
356	test drug arm. FDA recognizes that additional context may be needed to interpret such aggregate

- analysis results (e.g., if the aggregate event rate is higher in the active control group than in thetest drug group, it could be that the test drug is protective rather than that the control drug is
- causing an increased rate of the adverse event). For imbalances suggesting a substantially higher
- 360 rate in the control group (rather than a protective effect of the study drug), the sponsor should
- 361 report such an imbalance to FDA; FDA acknowledges that the reporting threshold for a well-
- 362 characterized approved control drug could be higher in light of previous knowledge of the drug.
- 363 The sponsor should consider sharing with the NDA or BLA holder the events that suggest a

Draft — Not for Implementation

364 365	higher rate in the active control group even if the events do not rise to the level of IND safety reporting.
366	
367	If the sponsor is not the NDA or BLA holder for the control drug, they are not expected to
368	perform aggregate analyses to assess whether there is an increased occurrence of serious
369	expected adverse reactions for the control drug (i.e., events reportable under § 312.32(c)(1)(iv)).
370	In general, it should be expected that the control drug is marketed and its safety profile is well
371	established and described in labeling. If, however, it becomes apparent that the expected serious
372	adverse reaction that is listed in the package insert of the control drug occurs at a much higher
373	frequency than is expected, the sponsor should report this finding to FDA in an IND safety
374	report.
375	
376	1. Events That Do Not Require Aggregate Analyses
377	
378	a. Individual occurrences (§ 312.32(c)(1)(i)(A))
379	
380	Certain SAEs are informative as single cases because they are "uncommon and known to be
381	strongly associated with drug exposure[.]" Some examples include angioedema, certain blood
382	dyscrasias (e.g., agranulocytosis), rhabdomyolysis, hepatic injury, anaphylaxis, and Stevens-
383	Johnson Syndrome. The occurrence of even one case of such adverse events would meet the
384	definition of <i>suspected adverse reaction</i> (i.e., there is a reasonable possibility that the drug
385	caused the event) and therefore must be reported in an IND safety report (§ 312.32(c)(1)(i)(A)).
386	
387	The blind should ordinarily be broken for these types of IND safety reports that are submitted to
388	FDA and all participating investigators. Knowledge of the treatment received is necessary for
389	interpreting the event and determining whether it is a suspected adverse reaction. Further, such
390	knowledge may be essential for the medical management of the subject and may provide critical
391	safety information about a drug that could have implications for the ongoing conduct of the trial
392	(e.g., monitoring, informed consent). FDA generally does not anticipate that unblinding single
393	or small numbers of serious and unexpected adverse event cases will compromise trial integrity,
394 205	in part because such unblinding should be infrequent. For example, a single case of liver injury
395	would be unblinded but would have no effect on overall study integrity. The challenges arising
396	from unblinding safety data for aggregate data analyses are discussed in sections VI.B through VI.D of this guidance.
397	VI.D of this guidance.
398	If the blind is buoken and a subject with an advance event that would meet the aritaria for
399 400	If the blind is broken and a subject with an adverse event that would meet the criteria for
400	reporting as a single event was receiving placebo, the event should not be reported in an IND safety report because it is not possible that the drug caused the adverse event. If the blind is
401	broken and this subject was receiving drug treatment (test drug or active comparator), it must be
402	reported in an IND safety report (\S 312.32(c)(1)(i)(A)).
403	reported in an IND safety report ($\frac{9}{9}$ 512.52(C)(1)(1)(A)).
404	b. One or more occurrences (\S 312.32(c)(1)(i)(B))
405	$0. \qquad \text{One of more occurrences } (8.512.52(c)(1)(1)(D))$
400	One or more occurrences of an SAE "that is not commonly associated with drug exposure but is
408	otherwise uncommon in the population exposed to the drug" meets the definition of a suspected
400	otherwise uncommon in the population exposed to the drug infects the definition of a suspected adverse respective and therefore must be reported in an IND sofety report (8,212,22(a)(1)(i)(D)). If

409 adverse reaction and therefore must be reported in an IND safety report (§ 312.32(c)(1)(i)(B)). If

Draft — Not for Implementation

410 411 412 413 414	the event occurs in association with other factors strongly suggesting causation (e.g., strong temporal association, event recurs on rechallenge), a single case may be sufficiently persuasive to report in an IND safety report. Often, more than one occurrence from one or multiple studies would be needed before the sponsor could determine that there is a <i>reasonable possibility</i> that the drug caused the event. Examples include tendon rupture or heart valve lesions in young
415 416	adults or intussusception in healthy infants. For reasons similar to those given above in section IV.A.1.a regarding individual occurrences, such events should be unblinded.
417	
418	2. Events That Require Aggregate Analyses
419	
420	a. Events anticipated to occur in the study population, independent of drug $(5, 212, 22(x)(1)(1)(2))$
421	exposure (§ 312.32(c)(1)(i)(C))
422 423	Contain SAEs can be entirinated to ecour in the study nonvilation independent of drug exposure
423	Certain SAEs can be anticipated to occur in the study population independent of drug exposure. Such events include:
425	Such events include.
426	• Events common in the study population, such as:
427	• Events common in the study population, such as.
428	- Events related to the underlying disease or condition under investigation (e.g., death
429	due to progressive disease in an oncology trial, pneumonia in participants with
430	chronic obstructive lung disease, diabetic ketoacidosis in a trial of type 1 diabetes
431	management, hospitalization for gait disturbance reported in a multiple sclerosis trial)
432	
433	- Events that are common in a population regardless of the underlying condition being
434	studied (e.g., cardiovascular events or hip fracture in an older adult population)
435	
436	• Events known to occur with drugs administered as part of a background regimen (e.g.,
437	neutropenia with a myelosuppressive chemotherapeutic agent, intracerebral hemorrhage
438	with an anticoagulant, cytomegalovirus colitis with an immunosuppressive regimen)
439	
440	Although these anticipated SAEs meet the definition of unexpected in § 312.32(a) because they
441	are not listed in the investigator's brochure (see section III.C of this guidance), they do not
442	warrant expedited reporting as individual cases or even when there are many such events where
443 444	the incidence is consistent with expected background rates in the study population. Such anticipated SAEs will occur even if the drug does not cause them, and their occurrence alone will
444	generally not support a conclusion that there is a reasonable possibility that the drug caused the
446	events. To assess whether the drug could have caused the SAE that is anticipated in the
447	population, the sponsor should perform an aggregate analysis that will enable an assessment of
448	whether the rates of the anticipated adverse event in a population exposed to the drug differ from
449	the rate of the same SAE in a similar population not exposed.
450	
451	Such anticipated adverse events should be monitored at appropriate intervals, and the numbers of
452	events in treated versus control trial participants should be compared using a safety monitoring
453	process that protects the integrity of blinding (see section VI.D of this guidance). The adverse
454	event must be reported to FDA in an IND safety report if an aggregate analysis reveals there is

455 an imbalance between arms that is sufficient to conclude that there is a reasonable possibility that

Draft — Not for Implementation

456 the drug caused the adverse event (\S 312.32(c)(1)(i)(C)). The sponsor should consider all 457 relevant drug development data (in addition to the clinical trial data) when determining whether 458 there is a reasonable possibility that the drug caused the adverse event. 459 460 b. Increased occurrence of serious suspected adverse reactions 461 (§ 312.32(c)(1)(iv)) 462 463 The sponsor must report any clinically important increase in the rate of a serious suspected 464 adverse reaction over that listed in the protocol or investigator's brochure (\$ 312.32(c)(1)(iv)). 465 An incidence rate for such suspected adverse reactions may not always be available, but when 466 one is available or can be estimated from data or analyses in the investigator's brochure (e.g., 467 from a table), a clinically important increase over that rate must be reported (\$ 312.32(c)(1)(iv)). 468 The sponsor should perform an aggregate analysis to compare the rate of a serious suspected 469 adverse reaction seen in the study to the rate listed in the protocol or investigator's brochure. 470 The decision about when to report is a matter of judgment based on a variety of factors, 471 including the study population, the nature and seriousness of the reaction, and the magnitude of 472 the observed increase in the incidence rate. Monitoring the rate of these events in a blinded trial 473 requires a systematic safety surveillance process that will protect the integrity of the trial; this is 474 discussed in section VI of this guidance. 475 476 B. **IND Safety Reporting Criteria for Aggregate Data** 477 478 Determining when the aggregate safety data provide evidence suggesting (1) a causal 479 relationship between the drug and a serious adverse medical outcome (e.g., myocardial ischemia) 480 or (2) that there has been a clinically important increase in the rate of an expected serious 481 adverse reaction (i.e., determining whether the reporting threshold has been met) is a complex 482 judgment. It is almost never a simple application of a planned statistical analysis, and the 483 determination may change as data accumulate. FDA recognizes that these determinations can be 484 difficult and require judgment. It may be helpful for sponsors to document in internal records all 485 aggregate analyses of SAEs, including those that are determined not to meet the reporting 486 threshold. This is because FDA will focus primarily on the robustness of the sponsor's process 487 and the reasoning underlying the sponsor's decision if, during FDA's review of trial safety data, 488 FDA reaches a different conclusion about whether an IND safety report was warranted. The 489 sponsor may also prespecify reporting thresholds in its safety surveillance plan that, if exceeded, 490 would lead to submission of an IND safety report.

- 491 492
- 1. Serious and Unexpected Suspected Adverse Reactions (§ 312.32(c)(1)(i)(C))
- 493
- As noted previously, for the purposes of IND safety reporting, a suspected adverse reaction
 means there is a *reasonable possibility* that the drug caused the event (i.e., evidence to suggest a
 causal relationship between the drug and the adverse event) (§ 312.32(a)). To interpret
 imbalances in aggregate data, clinical and statistical (if applicable) expertise will be needed to
 determine whether that reasonable possibility exists, based on the totality of available

499 information.

Draft — Not for Implementation

501 502	Factor	s to consider when determining whether the reasonable possibility threshold has been met:
502 503 504	•	Extent of the increase in incidence seen in the test group compared to the control groups
505 506	•	Evidence of a dose response
507 508 509 510	•	Temporal relationship (for example, early increase post drug initiation, such as drug- induced liver injury occurring in the usual 1- to 6-month window, or malignancy events occurring after a lag period between the dates of exposure and date of event onset)
510 511 512	•	Consistency of the increase in multiple trials
513 514	•	Presence of a plausible mechanism of action
515 516 517 518	•	Nonclinical evidence (from toxicology or pharmacology animal studies, genetic studies such as knock-out or knock-in mouse models, or human genetic data) to support the finding
519 520 521	•	Pharmacology of the drug (including results from receptor, transporter, or enzyme binding or activation studies, and animal models) and known class effects
522 523 524 525 526	•	Pattern across the study population (for example, the event is observed more frequently in individuals likely to be susceptible to it (e.g., acute kidney injury in individuals with prior chronic kidney disease, myocardial infarctions in older individuals or those with existing coronary heart disease, hyperkalemia in individuals on ACE inhibitors))
527 528 529 530	•	Occurrence of other potentially related adverse events (e.g., occurrence of both strokes and transient ischemic attacks, unexpectedly large increase in creatine kinase and events of rhabdomyolysis)
530 531 532 533		2. Increased Rate of Occurrence of Serious Suspected Adverse Reactions (§ 312.32(c)(1)(iv))
534 535 536 537 538 539 540	determ clinica Factor occurr elsewh	eviously recognized serious suspected adverse reactions, clinical judgment is needed to nine whether a suspected adverse reaction to the investigational drug is occurring at a ally important increased rate relative to the rate provided in the investigator's brochure. Is to consider when making the judgment may include (1) the size of the increase in rate of ence for the test drug treatment group over the rate listed in the investigator's brochure or here in the current IND application and (2) the consistency of the increase over time and multiple trials, if applicable.
541		

Draft — Not for Implementation

542 543 544

C. **Other Reporting Requirements**

1. Findings from Other Sources (§ 312.32(c)(1)(ii) and (iii))

545 546 The sponsor must also report any findings from clinical, epidemiological, or pooled analysis of 547 multiple studies and any findings from animal or in vitro testing that suggest a significant risk in 548 humans exposed to the drug (§ 312.32(c)(1)(ii) and (iii)). These reports are required for studies 549 from any source, regardless of whether they are conducted under the IND or by the sponsor (§ 550 312.32(c)(1)(ii) and (iii)). A finding that suggests a *significant risk* would "ordinarily . . . result 551 in a safety-related change in the protocol, informed consent, investigator brochure (excluding 552 routine updates of these documents), or other aspects of the overall conduct of the clinical 553 investigation." For example, actions often taken in response to a significant risk finding include (1) immediate revision of the informed consent, (2) intensification of subject monitoring, (3) 554 555 revised eligibility criteria or screening procedures, (4) enrollment hold, or (5) consideration of 556 discontinuation of the trial. The sponsor is also required to submit protocol amendments that 557 describe certain changes to the protocol (§ 312.30(b)) in addition to the IND safety report. 558 559 a.

560

Findings from other studies (§ 312.32(c)(1)(ii))

561 Findings that suggest a significant risk generally arise from ongoing or completed clinical 562 studies, pooled data from multiple studies, epidemiological studies, and published and 563 unpublished scientific papers. Findings from clinical studies that are subject to this requirement 564 are those that have not already been reported under 312.32(c)(1)(i). For example, any 565 significant risk finding from a drug interaction study, a study evaluating the OT interval, or a 566 study of a marketed drug would be reported under this provision. An example of such a finding 567 would be a significant prolongation of the QT interval in subjects receiving the investigational 568 product.

569 570

571

b. Findings from animal or in vitro testing (\S 312.32(c)(1)(iii))

572 Findings from animal studies, such as "carcinogenicity, mutagenicity, teratogenicity, or reports 573 of significant organ toxicity at or near the expected human exposure" are examples of the types 574 of findings that suggest a significant risk. Before reporting a finding to FDA, the sponsor should 575 use judgment to decide whether the finding suggests a significant risk in humans or is too 576 preliminary to interpret without replication or further investigation.

577 578

2. IND Safety Reports for Study Endpoints (§ 312.32(c)(5))

579 580 Generally, study endpoints refer to outcomes that sponsors are measuring to evaluate efficacy. 581 For trials designed to evaluate the effect of a drug on disease-related mortality or major 582 morbidity, endpoint information should be collected, tracked, and monitored, usually by a data 583 monitoring committee (DMC), during the course of the trial (see the guidance for clinical trial 584 sponsors Establishment and Operation of Clinical Trial Data Monitoring Committees (March 585 2006)). The study endpoints, including unblinded study endpoints, are not ordinarily reported in 586 IND safety reports, except when there is evidence of a causal relationship between the drug and 587 the event (\$ 312.32(c)(5)). For example, a death ordinarily would not be reported as an

Draft — Not for Implementation

individual case in an expedited report from a trial designed to compare all-cause mortality in subjects receiving either an investigational drug or a placebo. If, however, the death occurred as a result of an anaphylactic reaction that coincided with initial exposure to the drug or was the result of fatal hepatic necrosis, the death must be reported as an individual case in an IND safety report because of the evidence suggesting a causal relationship between the drug and the event (\$ 312.32(c)(5)). This is analogous to a single uncommon event required to be reported under \$ 312.32(c)(1)(i)(A).

596 In addition to the study endpoints described above, some trials also evaluate the effect of the 597 drug on several other pre-identified specific adverse events, often called *safety endpoints*. These 598 safety endpoints should be identified in the protocol and monitored and reported by the sponsor 599 as specified in the protocol.

600 601

602V.SYSTEMATIC APPROACH FOR REVIEW OF SAFETY INFORMATION603(§ 312.32(b))

604

Sponsors should have a systematic approach to safety surveillance¹⁴ to comply with the IND
safety reporting requirements and to improve the overall quality of safety reporting. Such an
approach should include a process for promptly reviewing, evaluating, and managing
accumulating data on SAEs from the entire drug development program that are sent from
domestic or foreign sources.

610

611 During the course of drug development, investigators who conduct clinical trials generally report 612 to the sponsor adverse event information; however, a sponsor may become aware of new safety 613 information from a variety of sources, both domestic and foreign.

614

The sponsor must review and evaluate safety information from any source regardless of whether the data came from studies conducted under the IND (§ 312.32(c)(1)(ii) and (iii)) to determine if there is a newly identified significant risk to trial participants.¹⁵ Sources include but are not limited to:

- 619 620
- Animal or in vitro studies
- Clinical or epidemiological investigations

⁶²² 623

¹⁴ For more discussion of this subject, see the guidance for clinical trial sponsors *Establishment and Operation of Clinical Trial Data Monitoring Committees* (March 2006), the guidance for industry *Premarketing Risk Assessment* (March 2005), and additional sources listed in the references section of this guidance.

¹⁵ Although sponsors must examine all information relevant to the safety of the drug obtained (§ 312.32(b)), not all safety information from available sources will need to be reported in an IND safety report. For example, sponsors do not have to submit to the IND spontaneous reports of adverse events for a drug marketed or approved in the United States resulting from commercial marketing experience for the same drug (see section VII.C of this guidance).

Draft — Not for Implementation

624	٠	Reports in the scientific literature, including unpublished reports of which the sponsor
625		becomes aware
626		
627	•	Information presented at professional or scientific meetings (e.g., abstracts)
628		
629	•	Reports from foreign regulatory authorities
630		
631	•	Reports from commercial marketing experience, including outside the United States
632		
633	The spo	onsor's review should include examining data from all sources and deciding whether the
634		ation meets the criteria for expedited reporting (see section IV of this guidance), as well as
635		ing all accumulating data at regular intervals to update safety information and to identify
636		fety signals. Monitoring the progress of investigations is necessary to identify previously
637		cted potential serious risks (§ 312.56(a)), to update investigator's brochures, protocols,
638		isent forms with new information on adverse events, and, when necessary, to take steps to
639		subjects (e.g., modifying dosing, participant selection, or monitoring) that will allow an
640		gational drug to be safely developed despite potential risks or to discontinue investigations
641	•	gs with unreasonable and significant risks (§ 312.56(d)).
642		
643		A. Prospective Development of a Plan for Safety Surveillance
644		
645	The pro	ospective development of a plan for assessing SAEs—particularly those SAEs that are
646	-	terpretable in the aggregate—and other important safety information is usually an
647	•	ant component of IND safety reporting. The plan (also referred to as a safety monitoring
648		hould describe processes and procedures for assessing SAEs and other important safety
649	-	ation in a drug development program.
650	morm	
651	A nlan	for safety surveillance should include descriptions of the following elements:
652	7 pian	for survey survemance should include descriptions of the following elements.
653	•	Clearly defined roles and responsibilities of the entities and participating individuals that
654	•	have responsibility for any or all of following: reviewing, analyzing, and making
655		decisions regarding IND safety reporting
656		decisions regarding hydr safety reporting
657	•	A plan for regular review of SAEs and other important safety information, with
658	•	
659		unblinding as necessary for interpretation
	_	
660	•	A process for aggregate safety reviews (see section VI of this guidance for considerations
661		for aggregate data analysis), including:
662		
663		- A list of adverse events that are anticipated for the study population that the sponsor
664		does not plan to report individually, regardless of the investigator's assessment of
665		causality. The preferred terms (PTs) for such events should be specified in a
666		standardized coding convention or dictionary such as MedDRA (Medical Dictionary
667		for Regulatory Activities). The events should each reflect a cohesive medical concept
668		and not necessarily a single PT: an event may be reflected by a number of different
669		PTs. For example, the serious event of myocardial infarction may include a range of

Draft — Not for Implementation

	Draft — Not for Implementation	
670	specific PTs. Thus, each anticipated serious event may be reflect	ed by a list of PTs
671	(see section VII. B of this guidance). Sponsors may discuss the a	inticipated SAEs
672	with the applicable FDA review division during protocol develop	-
673	trial initiation, as appropriate. It is not expected that the list of an	-
674	cover all clinical events that may be background clinical events i	1
675	hence, reported SAEs coding to PTs that are not on the anticipate	1 1 1
676	on the list of expected events) do not necessarily require IND saf	
677	Rather, such events should be carefully reviewed to determine if	
678	for IND safety reporting when such a determination cannot be m	
679	case.	C
680		
681	- For studies that will use a trigger approach (see section VI.B.1.a	of this guidance) to
682	decide when such SAEs should be unblinded, the predicted rates	-
683	and the basis for the predicted rates should be specified.	1
684		
685	– A plan to monitor the incidences of all events other than those th	at do not require
686	aggregate reporting (which would be reported without requiring	-
687	see section IV.A.1 above). These include anticipated events (bot	h pre-specified and
688	those not on the anticipated event list but reviewed and assessed	
689	background event in the population and hence not immediately re	eported) and
690	expected events (those listed in the package insert or investigator	's brochure).
691		
692	– The frequency with which aggregate reviews of safety data will b	be performed.
693		-
694	 Pre-planned assessments of the trial and program safety database 	when trials within
695	the program are completed and unblinded, when safety informati	on from trials of
696	other drugs in the same class are reported, or when any informati	on relevant to safety
697	is presented (e.g., pharmacology, toxicology, genetic).	
698		
699	 Methods that may be used to evaluate events, including graphical 	, tabular, or
700	statistical approaches.	
701		
702	 Unblinding practices and controls and processes for maintaining 	trial integrity.
703		
704	The sponsor should evaluate the safety surveillance plan as the development	
705	and the safety profile of the product evolves to determine whether the plan s	1
706	The plan should be maintained by the sponsor and must be available for FD.	-
707	required for all sponsor records and reports of an investigation under § 312.4	58(a).
708		
709		
710	VI. CONSIDERATIONS FOR AGGREGATE DATA ANALYSIS F	OR IND SAFETY
711	REPORTING	
712		
713	Analyses of aggregate data to identify imbalances for those events of the typ	
714	§§ 312.32(c)(1)(i)(C) or 312.32(c)(1)(iv)) generally will become more information development progresses and data accumulate. Unloss differences are large	e
715	development prograsses and data accumulate. Unloss differences are large	howayar detaction

715 development progresses and data accumulate. Unless differences are large, however, detection

Draft — Not for Implementation

716 of a clinically meaningful imbalance often requires a database of significant size. Regardless of 717 the size of the program, clinical judgment is important because imbalances of events between 718 arms may result from chance. Interpreting imbalances may be particularly challenging for 719 smaller programs where the number of events is small.¹⁶ Even nonstatistically significant 720 imbalances may be relevant, and interpretation may require a broader evaluation including 721 detailed assessment of trial data such as time to event, detailed case assessments, and reliance on 722 information outside of the trial, such as the pharmacology of the drug, class effects, and non-723 clinical findings. Waiting for a statistically significant difference in event rates, when other 724 evidence points to a potential causal association, may unduly delay reporting serious events of 725 concern. It is particularly difficult to detect differences in rates of adverse events that may be 726 anticipated in the population being studied but are not common (e.g., prostate cancer in middle-727 aged men). Recognizing the complexity of the judgements, FDA will focus on the sponsor's 728 process and reasoning underlying the sponsor's decision in the event the FDA and sponsor reach 729 different conclusions regarding whether SAEs evaluated by analyses of aggregate data meet IND 730 safety reporting criteria.

- 731
- 732 733

A. Identify Serious Adverse Events Anticipated to Occur in the Study Population

734 735 As discussed in section V of this guidance, regarding the safety surveillance plan, the first step in 736 preparing for an aggregate analysis of anticipated events is developing a list of these events in 737 the protocol or in the plan for safety surveillance and documenting a plan for monitoring these 738 events. This will enable the safety assessment team to identify events that should not be 739 individually reported in an IND safety report, even if they are assessed by the investigator as 740 drug-related. As discussed in section V.A above, the fact that the sponsor did not prospectively 741 identify an adverse event as anticipated in its safety surveillance plan does not mean that it needs 742 to be reported as a single event.

743

For drug development programs in rare diseases, external data sources used to establish anticipated adverse event rates are often limited. Furthermore, the clinical trial to support effectiveness may be an unblinded single-arm trial (i.e., a trial with no concurrent comparator group). These settings are especially challenging, and sponsors should use judgement in determining whether there is a reasonable possibility that the drug caused the event. Sponsors may wish to discuss their plans regarding when an anticipated adverse event should be reported as an IND safety report with the relevant review division.

751 752

B. Aggregate Analyses of Safety Data

753 754 755

1. Approach to Aggregate Analyses

For SAEs that are interpretable only based on aggregate data (reportable under

\$\$ 312.32(c)(1)(i)(C) and 312.32(c)(1)(iv)), the entity or entities that conduct the aggregate
analyses generally should use one of two possible approaches to identify events that are

¹⁶ For smaller programs, sponsors may need to assess events typically requiring aggregate analysis on an individual case basis and to only report if the event meets the criteria under 312.32(c)(1)(i)(A) or (B).

Draft — Not for Implementation

reportable. One approach (a) estimates and prespecifies the estimated background rate of the 759 760 event in the population (e.g., myocardial infarctions in an older adult population) and then 761 utilizes an *unblinding trigger* rate, based on the rate in the blinded data from the study 762 population. If that rate is exceeded, an unblinded analysis by treatment group is conducted. The 763 other approach (b) regularly analyzes unblinded safety data on SAEs by treatment group to 764 assess whether there is a meaningful increase in a particular event in the intervention group 765 compared to the control group. Appendix C illustrates these two approaches to aggregate 766 analyses.

767

Sponsors should have processes for comparing the rates of expected serious adverse reactions to
the rates listed in the protocol or investigator's brochure in order to determine whether they must
be reported under § 312.32(c)(1)(iv).

771 772

773

a. Unblinding trigger approach

774 In the unblinding trigger approach, if the results of the overall blinded analyses demonstrate that 775 the rate of events in the pooled treatment groups substantially exceeds the predicted rate, the next 776 step is to examine the rates by treatment group using an unblinded analysis. The trigger for 777 unblinding by group is that the overall rate for a particular adverse event is substantially higher 778 than the rate that was predicted for the overall study population. To follow this approach, 779 sponsors would prespecify predicted rates for the anticipated SAEs (note that this would involve 780 grouping events reported as preferred terms; see section VII.B of this guidance for information 781 about the importance of standardized coding). Once the unblinding trigger rate is met, the 782 numbers of events for the specific event in each arm would then be compared to determine 783 whether the IND safety reporting criteria in § 312.32(c)(1)(i)(C) have been met. The unblinding 784 trigger rate is set based on information available on anticipated events applicable to the specific 785 study population (based on age, comorbidities, concomitant treatments, etc.). This approach 786 allows for the detection of a possible increase in event rates in the treated population without 787 routine unblinding, and, if the trigger is met, with unblinding only of the event at issue. 788

789 Sponsors should use all available data, including placebo databases, historical data, literature,

- resternal epidemiological databases, electronic health records, and disease-specific registries, to
- rates of SAEs anticipated to occur in the study population. The predicted rates should
- be included in the plan for safety surveillance (see section V of this guidance).
- 793

794 FDA recognizes that it may be challenging to use a trigger approach because data on the rates of 795 some anticipated SAEs in the specific trial population are not always available. For example, 796 although it may be possible to find data on the rates of cardiovascular events in the general 797 population aged 40-70 years, data specific to a similarly aged population with rheumatoid 798 arthritis may not be available. In addition, even when population rates are available from 799 external sources, such as surveys or health care databases, if the population enrolled in a trial is 800 healthier than the general population from which the rate is derived, this could lead to a less 801 sensitive trigger rate (too high) than is appropriate for the trial population.

802

Therefore, a sponsor may choose to predict rates of certain anticipated SAEs, using a trigger
 approach, and to not predict rates of others. For example, many SAEs on the anticipated list, as

Draft — Not for Implementation

805 well as SAEs not placed on the anticipated list but assessed as background events, are not 806 interpretable as single events, but may be expected to occur relatively infrequently (e.g., sepsis or 807 hemorrhagic stroke or hip fracture), especially in a trial of relatively short duration (e.g., 3–6 808 months). Unblinding to assess incidence by treatment group may be specified for all such less 809 common events when, for example, four or five or more events (depending on the event) are 810 reported. One approach to setting the trigger for such less common background events is to 811 consider what imbalance would suggest a suspected adverse reaction and lead to submitting an 812 IND safety report. Such an assessment may include a detailed review of the individual events, 813 considering all of the factors listed in section IV.B.1 of this guidance. The rationale behind the 814 choice of events for which a prespecified threshold is identified is important, and the sponsor 815 should document how that threshold is determined.

816 817

818

b. Analyses of all events by treatment group

819 An alternative to the trigger approach is to conduct periodic aggregate analyses of all SAEs, or at 820 least those occurring in more than three or four participants (i.e., a cutpoint where the most 821 extreme unfavorable imbalance would raise concern), comparing numbers of those events across 822 treatment arms, to determine if there is a numerical imbalance that needs further evaluation to 823 determine whether the IND safety reporting criteria in \$ 312.32(c)(1)(i)(C) have been met. This 824 approach is preferable when it is not possible to accurately predict rates of anticipated SAEs. 825 This approach does not require identifying predicted rates of events and directly assesses rates in 826 treatment and control groups, the issue of primary interest. The routine unblinding of SAEs that 827 occurs with this approach requires scrupulous, thoroughly planned and well-documented efforts 828 to protect data integrity, assuring that the entity carrying out the review is completely firewalled 829 from the staff conducting the trial and assessing efficacy.

- 830
- 831 832

2.

Frequency of Aggregate Analyses

833 In the absence of a specific concern, it is reasonable to conduct the aggregate analyses at 834 intervals based on volume of safety data collected or based on subject accrual into the trial (e.g., 835 as each 25 percent of the recruitment target is reached) or on event rates (e.g., that might be 836 higher in a relatively sick study population). It is likely that the need to conduct aggregate 837 analysis will happen at regular intervals (e.g., 6 months or more frequently as appropriate). The 838 frequency may be modified, as needed, if safety concerns arise that require follow-up (e.g., an 839 imbalance might be determined not to require an IND safety report but could lead to more 840 frequent monitoring). In addition, in determining the appropriate frequency of aggregate 841 reviews, the sponsor should consider factors such as experience with the drug, the condition 842 being treated, the study population, and enrollment rates. The frequency of review and the 843 rationale behind it should be described in the plan for safety surveillance (see section V.B of this 844 guidance).

- 845
- 846

3. Considerations When Evaluating Aggregate Data

847
848 Aggregate analyses should generally be performed across multiple studies under the IND and, as
849 appropriate, across all INDs for the drug held by the sponsor, including both completed and
850 ongoing trials. Clinical and statistical judgment is needed to evaluate the totality of the

Draft — Not for Implementation

851 information related to a specific adverse event, including information from trials in different

populations, particularly when the trials have different study designs (e.g., different dosing
 schedules, varying durations of follow-up, different indications). FDA recognizes that these

differences between studies may make it difficult to compare event rates across trials; therefore.

documentation of this clinical assessment is recommended. The draft guidance for industry

856 Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs

857 or Biological Products (November 2018)¹⁷ provides recommendations regarding combining data
 858 from multiple trials.

- 859
- 860 861

C. Entities That Review Aggregate Data for IND Safety Reporting

862 Under § 312.32, sponsors are responsible for promptly reviewing all information relevant to the safety of the drug, determining whether safety information meets the IND safety reporting 863 criteria, notifying FDA and all participating investigators in an IND safety report of potential 864 865 serious risks, and promptly investigating all follow-up safety information it receives. Sponsors 866 may choose to designate an entity (an individual or group of individuals) to review the 867 accumulating safety information in a drug development program (e.g., over time in a late-stage 868 clinical trial, across trials, across INDs for the same drug) and to make a recommendation to the sponsor regarding whether the safety information must be reported under § 312.32.¹⁸ Sponsors 869 870 have flexibility in determining which entity or entities should perform this function. The entity 871 used to assess individual occurrences or a small number of adverse events (reported under § 872 312.32(c)(1)(i)(A) and (B)) may be different from the entity assessing aggregate adverse events 873 reported under § 312.32(c)(1)(i)(C).

- 874
- 875 876

1. Features and Composition of the Entity

The entity or entities reviewing aggregate safety information should include an individual or individuals with knowledge about the investigational drug; the disease being treated, including the epidemiology of the disease; and the characteristics of the study population (e.g., natural history of the disease being treated, background rates of anticipated adverse clinical events) and be qualified by training and experience to make clinical judgments about the safety of the drug. Identification of a new type of clinical safety concern (e.g., ocular toxicity, renal toxicity) may warrant adding additional expertise to the entity reviewing safety data.

The roles and responsibilities of each individual or group of individuals in the entity should be clearly defined in the plan for safety surveillance (see section V.A of this guidance).

887 888

889

2. Identifying the Entities that Review Safety Information

If a DMC is in place, the DMC may be used to conduct aggregate analyses to help the sponsor
assess whether the reporting criteria in §§ 312.32(c)(1)(i)(C) and 312.32(c)(1)(iv) have been met.
An advantage of having a DMC conduct this review is that the DMC routinely sees unblinded
data and can utilize existing controls for maintaining trial integrity. FDA recognizes that

¹⁷ When final, this guidance will represent FDA's current thinking on this topic.

¹⁸ See § 312.52 (Transfer of obligations to a contract research organization).

Draft — Not for Implementation

894 analyzing these data for the purpose of providing a recommendation to the sponsor regarding 895 whether the IND safety reporting criteria have been met would be a new role for most DMCs. 896 While DMCs monitor risks and benefits to make recommendations for trial continuation or 897 modification, entities that review safety information for the purpose of IND safety reporting 898 focus on identifying and characterizing risks of the test drug (i.e., suspected adverse reactions). 899 Although there is certainly overlap in these activities, the assessments may differ in certain 900 circumstances and the DMC could fulfill this new role by (1) reviewing the accumulating safety 901 data collected over time in late-stage drug development and across multiple trials, across INDs 902 for the particular drug, and from other sources, if applicable, and (2) assessing whether the IND 903 safety reporting criteria have been met. If this role is allocated to the DMC, the DMC charter 904 should reflect this new role.

905

906 If the sponsor does not use a DMC for the purpose of reviewing safety analyses to detect events 907 meeting the criteria for IND safety reporting, the sponsor should identify an entity within or 908 outside the sponsor's organization for this purpose. If the entity consists of more than one

909 individual, it may have both sponsor representation and/or external representation. It is

910 important that no unblinded effectiveness data, including references to masked treatment group

911 assignments (e.g., treatment groups A, B, or C), be revealed to internal or external personnel

912 participating in the conduct or analysis of an ongoing clinical trial program except for DMC

913 members and any personnel designated to conduct unblinded analyses of safety data and who 914 have been appropriately firewalled from those conducting the trial and performing other analyses

- 915 (See section VI.D of this guidance).
- 916

917 Sponsors may also consider a triage approach in which more than one entity participates in the 918 review. Blinded review by sponsor personnel most familiar with the product and program would 919 be conducted to determine if the number of events being seen in the trial population as a whole 920 meets certain criteria that would trigger an unblinded comparison of event rates in the treatment 921 and control groups. The unblinded analyses would be conducted by a separate firewalled 922 internal or external entity (e.g., a DMC). It is also possible that the initial unblinded analyses by 923 treatment group could be by an individual that is firewalled from the personnel responsible for conducting the trial, and only if there is an imbalance by treatment group¹⁹ would that individual 924 925 refer the events to an internal or external entity responsible for determining if the threshold for 926 IND reporting is met. Whatever approach a sponsor uses should be documented in the safety 927 surveillance plan.

- 928
- 929 930

933

934

935 936

937

D. Maintaining Trial Integrity When Reviewing Aggregate Data

Recommended steps to protect trial integrity include ensuring that:

- Internal personnel conducting unblinded safety reviews do not participate in the conduct or analysis of the trial or trials.
- Appropriate procedural controls and processes are prospectively specified in the safety surveillance plan to prevent sponsor personnel involved with the conduct or analysis of

¹⁹ It is possible that the number of events seen in the trial population is above expected but there is no imbalance between treatment groups.

Draft — Not for Implementation

938 the trial(s) from being unblinded to individual subjects' treatment assignments. If a 939 firewalled entity other than the DMC is set up to look at aggregate data, it should have 940 access only to the unblinded data necessary to evaluate the event. For example, it may be 941 necessary to unblind the treatment assignment of the subjects who experienced an SAE. 942 or it may be necessary to unblind additional data that is relevant to interpreting the 943 observed imbalance (e.g., related clinical adverse events). Study endpoints, efficacy data, 944 and other data collected for the trial that do not pertain to the adverse event should not be 945 unblinded.

FDA acknowledges that serious suspected adverse reactions may be unblinded at the site level if
knowledge of the treatment received is assessed as necessary for the medical management of the
subject.

950

946

951 To address sponsor concerns about unblinding large numbers of subjects' treatment assignments

to investigators when submitting aggregate reports, FDA considers the sending of the narrative

- 953 portion of the IND safety report based on data in the aggregate to all participating investigators,
- 954 instead of sending a completed Form FDA 3500A for each individual event, to meet the

955 requirement of § 312.32(c)(1) for a sponsor to notify all participating investigators in an IND 956 safety report of potential serious risks.

957

If the sponsor proposes and follows a reporting format different from that otherwise required in
§ 312.32(c), it must be agreed to in advance by the director of the FDA review division
responsible for reviewing the IND (§ 312.32(c)(3)).

961 962

VII. OTHER SAFETY REPORTING ISSUES

- 963 964
- 965 966

A. Alternative Reporting Arrangements (§ 312.32(c)(3))

967 The requirement in \$ 312.32(c)(1) specifies the format and time frame for reporting potentially 968 serious risks in an IND safety report (see section VIII of this guidance). Sponsors may request 969 and adopt different reporting formats or frequencies if agreed to in advance by the director of the 970 FDA review division responsible for reviewing the IND (§ 312.32(c)(3)). In addition, FDA may 971 require a sponsor to submit IND safety reports in a different format or at a different frequency 972 than required under § 312.32(c)(1) (see § 312.32(c)(3)). FDA may require a sponsor to continue 973 to report expeditiously a medically significant suspected adverse reaction that is listed in the 974 investigator's brochure as observed with the drug (i.e., expected) so that its rate can be carefully 975 monitored (\$ 312.32(c)(1)(v)). For example, if a single occurrence of Stevens-Johnson 976 Syndrome was observed in a subject receiving the investigational drug (and hence listed in the 977 investigator's brochure), FDA may nonetheless require expedited reporting of additional cases of 978 rash of a lesser severity. FDA may also require an alternative format or frequency for reporting 979 suspected adverse reactions. For example, once a drug has been identified as posing a potential 980 or previously unforeseen risk to participants in a clinical trial, FDA may require expedited 981 reporting of specific suspected adverse reactions for monitoring purposes. 982

Draft — Not for Implementation

983 B. Importance of Standardized Coding

984 985 As part of the sponsor's responsibility to promptly review all SAEs under § 312.32(b), sponsors 986 should review the verbatim (reported) term and how it was coded to a MedDRA preferred term 987 to ensure that coding was appropriate. To define these medical concepts, sponsors should plan to 988 prospectively group adverse event terms that represent closely related medical concepts (e.g., for 989 the medical concept of renal failure, appropriate preferred terms might include PTs of renal 990 failure, renal failure acute, renal failure chronic, renal impairment, acute prerenal failure, 991 azotemia, urine output decreased, postoperative renal failure, and other relevant terms). 992 Standardized MedDRA queries (SMQs) or Higher Level Terms (HLTs) or sponsor-defined 993 groupings that reflect the anticipated event should be employed. See the guidance for industry 994 Premarketing Risk Assessment (March 2005) for additional discussion of coding.

995 996 997

C. Investigations of Marketed Drugs (§ 312.32(c)(4))

998 According to § 312.32(c)(4), a sponsor of a clinical study of a drug marketed or approved in the 999 United States that is conducted under an IND must submit IND safety reports for suspected 1000 adverse reactions that meet reporting criteria under § 312.32 and are observed in the study at domestic or foreign sites. If the sponsor is not the NDA or BLA holder,²⁰ the sponsor should 1001 1002 also forward the report to the NDA or BLA holder, manufacturer, packer, or distributor of the 1003 marketed drug. If the sponsor is also the NDA or BLA holder, the sponsor must also submit 1004 safety information from the clinical study as prescribed by the relevant postmarketing safety 1005 reporting requirements (e.g., under §§ 314.80 or 600.80).

1006

1007 In addition, under § 312.32(c)(1)(ii) a sponsor must report events from other studies, including 1008 clinical studies that are not conducted under an IND or by the sponsor, that suggest a significant 1009 risk in humans exposed to the drug. Generally, such a finding would result in a safety-related 1010 change in the protocol, informed consent, investigator brochure, or other aspect of study conduct. 1011 Therefore, as long as the sponsor maintains an open IND for its marketed or approved drug, 1012 safety information from foreign and domestic studies, including non-IND studies, must be 1013 reported to the IND. If the sponsor is also the NDA or BLA holder, such safety information 1014 must be reported in accordance with the postmarketing requirements if it also meets the criteria 1015 for reporting. 1016

1017 If the IND sponsor (who may also be the NDA or BLA holder) for a drug approved in the United

1018 States becomes aware of a spontaneous report of an adverse event from U.S. or foreign

- 1019 commercial marketing experience for the drug that is under investigation (i.e., an experience
- 1020 occurring outside of a clinical trial), the report would be submitted based on required
- 1021 postmarketing reporting and does not also need to be submitted to the IND, even if it meets
- 1022 criteria for being a serious and unexpected suspected adverse reaction.
- 1023

 $^{^{20}}$ We note that the postmarketing reporting requirements concerning the submission of postmarketing 15-day Alert reports (§ 314.80(c)(1)(i) through (ii)) apply not only to the NDA or BLA holder but also to any other person whose name appears on the label of an approved drug product as the manufacturer, packer, or distributor of the marketed drug. See § 314.80(c)(1)(iii).

Draft — Not for Implementation

1024 If a drug is **not approved and not marketed in the United States** but is approved outside the 1025 United States, a sponsor conducting a study under an IND must submit an IND safety report for 1026 adverse reactions received through foreign commercial marketing experience if the event meets 1027 reporting criteria for IND safety reports (§ 312.32(c)(1)). Because the drug is not approved and 1028 is not marketed in the United States, such reports would not come to FDA as a postmarketing 1029 report. Therefore, the only way for FDA to receive such safety information is through the IND 1030 for the investigational product.

- 1031
- 1032 1033

D. Duration of Safety Reporting

The purpose of sending IND safety reports to investigators is to provide investigators with information they need to protect subjects participating in clinical trials. Once investigators are no longer enrolling or monitoring subjects and the site is officially closed, this information is no longer necessary. Cutoff dates for sending IND safety reports to investigators may be described in the protocol. If no cutoff dates are specified, once a site has been officially closed out, the sponsor usually does not need to continue sending IND safety reports to that site, and an investigator does not need to receive or review them. See *generally* § 312.32(c)(1).

1041

In unusual cases, safety information related to delayed toxicity may be reported after a site is officially closed out. For example, if a late toxicity is discovered that would affect subjects who received the investigational drug, the investigator should be notified so subjects can be followed up with if necessary (e.g., serious unexpected suspected adverse reactions that are detected and reported during the long-term follow-up for gene therapy products).

1047 1048

1049 VIII. SUBMITTING AN IND SAFETY REPORT (§ 312.32 (c)(1)(v))²¹

1050 1051

1052

1056

1057 1058

1059 1060

1061

1062

A. Report Identification and Format

Each report must prominently identify its contents (§ 312.32(c)(1)(v)). Reports should be
labeled as follows:

- "IND Safety Report" for 15-day reports
- "Follow-up IND Safety Report" for follow-up information
- "7-day IND Safety Report" for unexpected fatal or life-threatening adverse reaction reports

²¹ Under section 745A(a) of the FD&C Act, at least 24 months after issuance of the final guidance document in which FDA has specified the electronic format for submitting submission types to the Agency, such content must be submitted electronically and in the format specified by FDA. (See the draft guidance for industry *Providing Regulatory Submissions in Electronic Format: IND Safety Reports* (October 2019). When final, this guidance will represent FDA's current thinking on this topic.)

Draft — Not for Implementation

1063 1064 1065	For reports made on Form FDA 3500A, the type of report should be checked in box G6 on FDA Form 3500A.
1066 1067	The format for IND safety reports should be based on whether the report involves an individual case or events identified by aggregate analysis.
1068 1069	1. Individual Cases
1070	
1071	For reports of individual cases, a sponsor should ordinarily use Form FDA 3500A. ²² FDA will
1072	accept foreign suspected adverse reaction reports on a CIOMS I Form instead of Form FDA
1073	3500A (§ 312.32(c)(1)(v)). These forms should be completed with all available information,
1074	including a brief narrative describing the suspected adverse reaction and any other relevant
1075	information. Like all other IND safety reports, the narrative must also include identification of
1076	all previously submitted IND safety reports concerning a similar suspected adverse reaction and
1077	an analysis of the significance of the suspected adverse reaction in light of previous, similar
1078	reports or any other relevant information (§ 312.32(c)(1)). Sponsors should include the
1079	manufacturer report number for previously submitted IND safety reports for identification
1080	purposes.
1081	
1082	2. <i>Reports of Events Identified by Aggregate Analyses</i>
1083	
1084	IND safety reports required for submission based on aggregate analyses must be submitted to
1085	FDA in the format of a narrative summary report. See § 312.32(c)(v). The narrative summary
1086	report should include a summary of the analysis of the individual cases and should list the unique
1087	case identifiers for each case (or copies of such individual cases if they have not been previously
1088	submitted) that are reportable because of aggregate analysis findings. Sponsors should use
1089	judgment in deciding what to include in the summary of the analysis. Generally, this summary
1090	should include:
1091	1. A description of the array of a drame respection along with a brief grant ll array of
1092	1. A description of the suspected adverse reaction, along with a brief overall summary of
1093 1094	the cases. This summary could include demographic factors, symptoms, comorbid
1094	conditions, medical history, pertinent test results, concomitant medications, and timing of
1095	events relative to drug exposure.
1090	2. A description of the characteristics and results of the analysis, including a description of
1097	2. A description of the characteristics and results of the analysis, including a description of the safety data sources, how the conclusion was reached, who reviewed the analysis, any
1098	planned changes in monitoring or to study documents (e.g., informed consent,
1100	investigator's brochure), and any additional analyses planned.
1100	investigator s brocharc), and any additional analyses plained.
1101	Additionally, the narrative summary report must identify previously submitted IND safety
1102	reports concerning a similar suspected adverse reaction, and the sponsor must analyze the
1105	significance of the suspected adverse reaction in light of previous, similar reports or any other
1105	relevant information (\S 312.32(c)(1)). For example, if the sponsor plans to submit an IND safety
1106	report for pulmonary embolus, the sponsor should look to see if IND safety reports were
-	

²² Form FDA 3500A is available at http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm.

Draft — Not for Implementation

previously submitted for other thrombotic events (e.g., deep vein thrombosis) to analyze the occurrence of medically related adverse events. Similarly, for an IND safety report for fracture, the sponsor should consider whether IND safety reports previously submitted for falls are relevant to the analysis of the significance of the event. Narrative summary reports and other reports required to be submitted in narrative format under § 312.32(c)(1)(v) (see section VIII.A.3)

- 1112 of this guidance) should not be submitted on Form FDA 3500A, which is for individual-case
- 1113 safety reports consisting of individual subject data.
- 1114

1115 At the time the narrative summary report is submitted, the sponsor should submit all reports for 1116 the individual cases that made up the analysis that were identified in the narrative summary report

1117 (e.g., a completed FDA Form 3500A for each case), if not previously submitted. If individual cases

were previously submitted as IND safety reports in electronic common technical document
 (eCTD) format, the sponsor should list the eCTD sequence number²³ and date of submission

- 1119 (eCTD) format, the sponsor should list the eCTD sequence number²³ and date of submission 1120 with a hyperlink to the IND safety report to facilitate review. For INDs that are not in eCTD
- format, sponsors should attach previously submitted IND safety reports as PDF attachments to
- the narrative summary report and clearly identify them as duplicate submissions.²⁴ Before
- 1122 une narranve summary report and clearly identify mem as duplicate submissions.⁻⁻ Before
- submission to FDA, each individual case report should be unblinded to include data that is necessary to evaluate the event. FDA considers sending only the narrative summary report to
- necessary to evaluate the event. FDA considers sending only the narrative summary report to participating investigators without the individual unblinded case safety reports that are
- participating investigators without the individual unblinded case safety reports that are summarized in the narrative report to meet the requirement under § 312.32(c)(1) for a sponsor to
- notify all participating investigators in an IND safety report of potential serious risks.
- 1128

1129 For aggregate analysis, after an adverse event anticipated to occur in the study population is

- reported under 312.32(c)(1)(i)(C) or the increased rate of occurrence of an expected serious
- 1131 suspected adverse reaction is reported under 312.32(c)(1)(iv), the investigator's brochure, the 1132 protocol, and other safety-related information should be updated as appropriate and as soon as
- 1133 possible during the conduct of the ongoing clinical trial. After the anticipated event is listed in
- 1134 the investigator's brochure, the event should no longer be reported in IND safety reports because
- 1135 it would then be considered expected, unless there is a clinically important increase in the event
- 1136 rate. Similarly, the increased rate of occurrence of an expected serious suspected adverse
- reaction reported under § 312.32(c)(1)(iv) should no longer be reported in IND safety reports
- 1138 after the investigator's brochure, the protocol, and other safety-related information have been
- 1139 updated to reflect the updated rate of occurrence, unless a further increase in occurrence is
- 1140 observed and meets the reporting criteria.
- 1141
- 1142 The IND sponsor should in some circumstances develop, in consultation with the FDA review
- 1143 division and other safety oversight bodies (e.g., a DMC), an approach for reporting subsequent
- 1144 occurrences of certain events in an IND safety report that the sponsor has added, as expected
- 1145 events, to the investigator's brochure, the protocol, and other safety related information.
- 1146 Although IND safety reporting is no longer required after an SAE is listed in the investigator

²³ The eCTD sequence number is the unique four-digit number for each IND submission the sponsor submits in the us-regional.xml file for the eCTD submission.

²⁴ For more information see the draft guidance for industry *Providing Regulatory Submissions in Electronic Format: IND Safety Reports* and the technical specifications documents *Electronic Submissions of IND Safety Reports Technical Conformance Guide* (October 2019) and *Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments* (October 2019).

Draft — Not for Implementation

brochure, ongoing reporting of subsequent events may still be appropriate. For example, for 1147 1148 certain events that are infrequent with immediate health implications or an event that is 1149 uncommon in a specific study population (e.g., stroke in young adults) prompt notification of 1150 subsequent events after the first IND safety report may be warranted to ensure that the risk: 1151 benefit ratio remains acceptable to continue the trial. See § 312.56(d). A plan for reporting 1152 should be developed in consultation with the FDA review division and other safety oversight 1153 bodies (e.g., a DMC). For an event that is known to occur independent of drug exposure in the 1154 study population, the sponsor may specifically describe an approach for reporting to FDA and all 1155 participating investigators (e.g., an updated aggregate narrative summary report once a certain 1156 number of additional cases are identified or after a specified period of time, as appropriate). 1157 Additionally, the sponsor must submit to FDA any additional data or information that FDA deems necessary as soon as possible but in no case later than 15 calendar days after receiving the 1158 1159 request (§ 312.32(c)(1)(v)).

1160 1161

3. Other Reports

For reports of overall findings or pooled analyses from published and unpublished in vitro,
animal, epidemiological, or clinical studies, a narrative format must be used (§ 312.32(c)(1)(v)).
If the findings are published, in full or in abstract form, the sponsor should include a copy of the
publication.

1167 1168

B. Where and How to Submit

1169 1170 The IND safety report must be transmitted to the Center for Drug Evaluation and Research 1171 (CDER) or the Center for Biologics Evaluation Research (CBER) review division responsible for 1172 reviewing the IND (\S 312.32(c)(1)(v)). IND safety reports should be submitted to all of the 1173 sponsor's INDs under which the drug is being administered. For example, if a drug is found to 1174 cause drug-induced liver injury, this should be reported to any IND under which the drug is being administered. The sponsor should reference in the subject line of the cover letter all INDs 1175 1176 to which the IND safety report is being submitted. If applicable, the sponsor should also identify 1177 (e.g., by underlining) the specific IND under which the suspected adverse reaction occurred (e.g., 1178 "Suspected adverse reaction occurred under IND XXXX1, reference to INDs XXXX2, 1179 XXXX3"). 1180

1181 FDA recommends that sponsors submit IND safety reports electronically in the $eCTD^{25}$ if the

1182 IND is in eCTD format or if the sponsor intends to convert the IND to eCTD format. Complete

1183 information on eCTD specifications and guidance can be found on the FDA eCTD website, and

- assistance may be obtained by contacting <u>ESUB@fda.hhs.gov</u>. If the IND is not in eCTD
- 1185 format, other means of rapid communication (e.g., telephone, fax, email) may be used. If the
- 1186 IND is not in eCTD format and the sponsor intends to submit IND safety reports by fax or email,

²⁵ Although FDA has exempted noncommercial INDs from the electronic submissions requirements under section 745A(a) of the FD&C Act, FDA also accepts electronic submissions from these INDs. For additional information on this subject, see the guidance for industry *Providing Regulatory Submissions in Electronic Format*—*Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* (February 2020).

Draft — Not for Implementation

the sponsor should address the submissions to the Regulatory Project Manager and the Chief,
Project Management Staff in the FDA review division that has responsibility for review of the
IND. In addition, if the sponsor intends to submit IND safety reports by email, FDA
recommends that the sponsor obtain a secure email account with FDA.²⁶

- 1191
- 1192

C. Reporting Time Frame

1193 1194 The time frame for submitting an IND safety report to FDA and all participating investigators is 1195 as soon as possible but no later than 15 calendar days after the sponsor determines that the 1196 suspected adverse reaction or other information qualifies for reporting (\S 312.32(c)(1)). The 1197 IND safety reporting regulations were modified describing the reporting time frame applicable to 1198 IND safety reports of more than one event (e.g., reports of events qualifying for reporting under 1199 § 312.32(c)(1)(i)(B) and (C) and increases in rates of occurrence of serious suspected adverse 1200 reactions (§ 312.32(c)(1)(iv)), because these events generally require more than one occurrence 1201 to make the determination that the event meets the criteria for reporting. Thus, the date of initial 1202 receipt of the first event would likely be well before it was determined that the information must 1203 be reported.

1204

1205 FDA expects that events that are interpretable as single cases (i.e., uncommon and known to be 1206 strongly associated with drug exposure) will be reported to FDA within 15 calendar days from 1207 sponsor's initial receipt of the information because it will be immediately apparent that such 1208 events meet the reporting criteria (\$312.32(c)(1)). For events that require more than one 1209 occurrence to assess causality and events evaluated in the aggregate, the time clock starts from 1210 whatever date the sponsor determines that the events qualify for expedited reporting. This means 1211 that, for example, incomplete cases must be promptly followed up for additional information so 1212 that a determination can be made about whether the event is reportable as an IND safety report (§ 1213 312.32(d)).

1214

Under § 312.32(d)(3), if the results of a sponsor's investigation show that an adverse event not 1215 1216 initially determined to be reportable under paragraph (c) of this section is determined to be 1217 reportable, the sponsor must report such a suspected adverse reaction in an IND safety report as 1218 soon as possible but in no case later than 15 calendar days after the determination is made. This 1219 applies to reporting of single and aggregate events and to events that would individually or in the 1220 aggregate qualify for either 7- or 15-day reporting. FDA expects that any entity responsible for 1221 making recommendations to the sponsor regarding submitting an IND safety report based on 1222 aggregate data will promptly provide the recommendation to the sponsor so that the sponsor can 1223 meet its obligations under § 312.32. The sponsor must promptly review the information to 1224 determine whether the IND safety reporting criteria have been met (§ 312.32(b)).

1225

Unexpected fatal or life-threatening suspected adverse reactions represent especially important
safety information and must be reported more rapidly to FDA (§ 312.32(c)(2)). The requirement
for reporting any unexpected fatal or life-threatening suspected adverse reaction to FDA is as

soon as possible but no later than 7 calendar days after the sponsor's initial receipt of the

²⁶ For details on obtaining a secure email account with FDA, visit <u>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/d</u> <u>efault.htm</u>.

Draft — Not for Implementation

information (§ 312.32(c)(2)). If the safety report submitted within 7 calendar days is complete,
an additional submission within 15 calendar days from day zero is not required.

1232

1233 Day zero is considered as (1) the day the sponsor initially receives information for a case that is 1234 interpretable as a single case or (2) the day the sponsor determines that multiple cases qualify for 1235 expedited reporting.

1236

1237 If FDA requests any additional data or information, the sponsor must submit it to FDA as soon as 1238 possible but no later than 15 calendar days after receiving the request (\S 312.32(c)(1)(v)). See

1239 section IX of this guidance for reporting time frames for follow-up information.

1240

Finally, because of the potential for delay between the occurrence of an adverse event and the reporting of the adverse event to the sponsor, the date of the event on Form FDA 3500A is not determined by the reporting time frames and is "the actual or best estimate of the date of first onset of the adverse event." FDA interprets the "date of first onset of the adverse event"²⁷ to be the date that the subject first experienced the symptoms that were related to the adverse event. FDA recognizes that this determination is not always straightforward and requires clinical

1247 judgment to relate the prodromal symptoms to the adverse event.

1248 1249

1250 IX. FOLLOW-UP INFORMATION (§ 312.32(d)) 1251

1252 Most IND safety reports are derived from observations from clinical trials. In the setting of a 1253 clinical trial, information is usually collected in a controlled environment so that the information 1254 needed to evaluate the suspected adverse reaction (e.g., information that would be contained in a 1255 narrative report or on Form FDA 3500A) is generally readily available. If any information 1256 necessary to evaluate the suspected adverse reaction is missing or unknown, the sponsor should 1257 actively seek such information from the source of the report. In the event that the participant 1258 withdraws consent from participating in a clinical trial, FDA recognizes that the sponsor cannot 1259 continue to provide adverse event reports related to that subject once the consent is withdrawn 1260 unless those reports are associated with publicly available records.

1261

Any relevant additional information obtained by the sponsor that pertains to a previously
submitted IND safety report must be submitted as a Follow-up IND Safety Report without delay,
as soon as the information is available (§ 312.32(d)(2)) but should be submitted no later than 15
calendar days after the sponsor receives the information. The sponsor should maintain records of
its efforts to obtain additional information.

1267

For example, if information on concomitant medications is obtained after the initial IND safety report is submitted, and such information is relevant to evaluating the suspected adverse reaction,

1270 a sponsor must immediately submit a Follow-up IND Safety Report (§ 312.32(d)(2)). However,

1271 if the sponsor obtains other information that is not relevant to evaluating the suspected adverse

- reaction, records of such information should be maintained by the sponsor and, if applicable,
- submitted in an information amendment (§ 312.31) or in an IND annual report (§ 312.33).

²⁷ See Form FDA 3500A Supplement (4/16) – Form Instructions, available at <u>https://www.fda.gov/media/82655/download</u>.

Draft — Not for Implementation

1274

To help sponsors determine whether follow-up information is relevant to an IND safety report,
FDA provides in this section additional guidance on the types of information that generally
would require a follow-up IND safety report.

1277

1279 For an individual case that was submitted as an IND safety report under § 312.32(c)(1)(i)(A) and

1280 (B), examples of the types of information that trigger the follow-up IND safety reporting

- requirements include (1) a change in diagnosis of the adverse event, (2) important change in
- outcome of the adverse event (e.g., death), (3) autopsy findings, and (4) other new informationthat significantly impacts the assessment of causality.
- 1283 1284

1285 For aggregate data that were submitted as an IND safety report under \$\$ 312.32(c)(1)(i)(C) and 312.32(c)(1)(iv), examples of the type of information that would trigger follow-up IND safety 1286 1287 reporting requirements include: (1) additional occurrences of the adverse event that, in the 1288 aggregate, suggest a significant change in the rate of occurrence from the initial aggregate report, 1289 and (2) information about individual events that comprise the aggregate report that significantly 1290 impacts the assessment of causality such that there is no longer a reasonable possibility that the 1291 drug caused the event or strengthens the causal relationship between the adverse event and the 1292 drug. The sponsor should evaluate whether additional occurrences of the adverse event represent 1293 a clinically important increase in the rate of a serious suspected adverse reaction over that listed 1294 in the protocol or investigator's brochure, which must be reported under 312.32(c)(1)(iv). 1295

- 1295 1296
- 1290

X. SAFETY REPORTING REQUIREMENTS FOR BA AND BE STUDIES

1298 1299 The IND safety reporting requirements under § 312.32 apply to BA and BE studies that are 1300 conducted under an IND. BA and BE studies that meet the conditions for IND exemption under 1301 § 320.31(d) are not conducted under an IND and are not subject to the IND safety reporting 1302 requirements. Earlier iterations of § 320.31(d) that also exempted certain in vivo BA and BE 1303 studies in humans from the requirements of part 312, including the IND safety reporting 1304 requirements under § 312.32, did not establish separate safety reporting requirements for these 1305 studies. As FDA stated in its preamble to the final rule updating § 320.31(d) in 2010, the 1306 Agency determined that "the occurrence of a serious adverse event is very unusual in a [BA or 1307 BE] study because the number of subjects enrolled in the study is small, the subjects are usually healthy volunteers, and drug exposure is typically brief."²⁸ However, for these same reasons, 1308 1309 "the occurrence of any serious adverse event [in a BA or BE study] is of interest." Therefore, 1310 FDA revised § 320.31(d) to require reporting of SAEs as one of the conditions under which 1311 certain BA and BE studies are exempt from the requirements of part 312, including from the 1312 IND safety reporting requirements in § 312.32. See § 320.31(d)(3).

1313

1314 Timely review of this safety information is critical to ensuring the safety of BA/BE study

subjects, whether they are healthy volunteers or individuals with the specified medical condition

1316 and whether the trial has a single-dose or steady-state design.

²⁸ Final Rule, Investigational New Drug Safety Reporting Requirements for Human Drug and Biological roducts and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans (75 FR 59953) published September 29, 2010.

Draft — Not for Implementation

1317 1318 Α. BA/BE Study Safety Reporting Requirements (§ 320.31(d)(3)) 1319 1320 The company conducting an IND-exempt BA or BE study, including any contract research 1321 organization, must notify FDA and all participating investigators of any SAE observed for the 1322 test or reference drug during conduct of the study, regardless of whether the event is considered 1323 drug-related, as soon as possible but in no case later than 15 calendar days after becoming aware 1324 of its occurrence (§ 320.31(d)(3)). This includes, for example, SAEs listed in the reference listed 1325 product's approved labeling, the investigator's brochure, and the protocol. 1326 1327 If any information necessary to evaluate the SAE is missing or unknown, the company 1328 conducting the study should actively seek such information and maintain records of efforts to 1329 obtain additional information. Any relevant additional information obtained that pertains to a 1330 previously submitted safety report must be submitted as a Follow-up 1331 Bioavailability/Bioequivalence Safety Report as soon as the information is available (§ 1332 320.31(d)(3) but should be submitted no later than 15 calendar days after the company receives 1333 the information. In addition, upon request from FDA, the company conducting the study must 1334 submit to FDA any additional data or information that FDA deems necessary as soon as possible 1335 but in no case later than 15 calendar days after receiving the request (e.g., hospital record, 1336 autopsy report) (\$ 320.31(d)(3)). Study drug exposure for the subject who experienced the SAE 1337 should be unblinded. 1338 1339 If the adverse event is fatal or life-threatening, the company conducting the study must also 1340 notify the Director in CDER's Office of Generic Drugs as soon as possible but in no case later 1341 than 7 calendar days after becoming aware of its occurrence (\S 320.31(d)(3)). In doing so, the 1342 company should also notify the appropriate review division in CDER's Office of New Drugs or 1343 the Clinical Safety Surveillance Staff in CDER's Office of Generic Drugs. 1344 1345 The requirements under \$ 320.31(d)(3) do not apply to human BA and BE studies that are 1346 exempt from IND requirements and conducted outside the United States. However, as part of 1347 the information required to establish that the proposed drug product can be expected to have the 1348 same therapeutic effect as the reference listed product, adverse event information from foreign 1349 clinical studies must be included in the NDA supplement or the abbreviated new drug application (ANDA) submission as appropriate, based on the purpose of the BA/BE study.²⁹ 1350 1351 1352 B. How and Where to Submit a Report (§ 320.31(d)(3)) 1353 1354 For a BA/BE study conducted to support changes to an already approved NDA or abbreviated 1355 new drug application (ANDA), SAE reports must be submitted to FDA and should be submitted 1356 to the FDA Adverse Event Reporting System (FAERS). 1357 1358 For a BA/BE study conducted to support a new ANDA for a generic drug product, the entity 1359 conducting or sponsoring the study should request a pre-assigned application number at

²⁹ See 21 CFR 314.50(d)(5)(iv) and 75 FR 59935 at 59954 (September 29, 2010) (interpreting 21 CFR 314.97(a)(7) to require adverse event reports that occurred in foreign clinical studies to be included in the ANDA submission).

Draft — Not for Implementation

1360 1361 1362 1363 1364	https://www.fda.gov/drugs/developmentapprovalprocess/formssubmissionrequirements/electroni csubmissions/ucm114027.htm. FDA recommends requesting this application number prior to starting the BA/BE study, to avoid delays in expedited reporting. As stated on the website, it can take up to 3 business days following the online request to receive the pre-assigned application number.
1365 1366	The entity should use this application number for the following:
1367 1368 1369	1. Submission of all adverse event reports from BA/BE studies
1309 1370 1371	2. Submission of the ANDA for the test drug, when complete
1372 1373 1374	FDA encourages electronic submission of BA/BE safety reports to FAERS. FDA provides two methods for electronically submitting safety reports from BA/BE studies conducted to support the approval of generic drugs:
1375 1376	1. FAERS Database-to-Database (E2B) Transmission
1377 1378 1379 1380 1381	• For more information about adverse event reporting via E2B submission, visit <u>https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillanc</u> <u>e/adversedrugeffects/ucm115894.htm</u> .
1381 1382 1383 1384 1385	2. HHS Safety Reporting Portal (SRP) submission, available at <u>https://www.safetyreporting.hhs.gov/SRP2/en/Home.aspx?sid=3e955502-ce7f-4112-b379-87967ae2e4be</u> .
1385 1386 1387 1388	• The portal requires entering the six-digit pre-application ANDA number for submission of an adverse event report.
1389 1390 1391 1392 1393	For fatal or life-threatening adverse events that require 7-day expedited reporting, notifications generally submitted via E2B or SRP, FAERS will automatically route the submissions to the appropriate group in the Office of Generic Drugs for review. In situations when the E2B and SRP routes of submission are unavailable, sponsors should submit expedited reports of SAEs from BA/BE studies via email to <u>OGD-PremarketSafetyReports@fda.hhs.gov</u> .
1394 1395 1396 1397 1398 1399 1400	SAE reports not submitted via E2B transmission or the SRP should be submitted to FDA via email using Form FDA 3500A completed with all the available information, including a brief narrative describing the SAE, an assessment of causality, and any other relevant information (§ 320.31(d)(3)). If applicable, the narrative should also include identification of other similar reports and an analysis of the significance of the SAE. A summary of the study protocol should be submitted with the report.
1401 1402 1403	Each report must prominently identify its contents (§ 320.31(d)(3)). Reports should be labeled as follows:
1404 1405	• "Bioavailability/Bioequivalence Safety Report" for 15-day reports

Draft — Not for Implementation

1406	
1407	• "Follow-up Bioavailability/Bioequivalence Safety Report" for follow-up information
1408	
1409	• "7-day Bioavailability/Bioequivalence Safety Report" for unexpected fatal or life-
1410	threatening adverse reaction reports
1411	
1412	Box G4 of Form FDA 3500A should include the pre-application ANDA number, and the "Pre-
1413	ANDA" box should be checked. The type of report should be checked in box G6 on Form FDA
1414	3500A. The report can also be identified in box B5 and/or in a cover letter submitted with Form
1415	FDA 3500A.
1416	
1417	Each field in the "C" subsection of Form FDA 3500A should be completed appropriately. For
1418	example, in box C1, the study drug or drugs to which the subject was exposed prior to onset of
1419	the SAE should be listed (this may include active drug, placebo, and/or vehicle depending on the
1420	study). In box C2, the subject's concomitant medications should be listed. If the SAE began
1421	prior to administration of a study drug but after study enrollment, this event should not be
1422	submitted, because it is unassociated with study drug exposure. In box B5, the timeline of drug
1423	exposures as they relate to the SAE or SAEs should be clearly described.
1424	
1425	

	Draft — Not for Implementation
1426	REFERENCES
1427	
1428	For additional information on a systematic approach to safety surveillance, please refer to the
1429	following:
1430	
1431	Literature:
1432	
1433	Council for International Organizations of Medical Sciences (CIOMS), Management of
1434	Safety Information from Clinical Trials, Report of CIOMS Working Group VI, Geneva 2005,
1435	ISBN 92 9036 079 8.
1436	
1437	Crowe, BJ, HA Xia, JA Berlin, DJ Watson, H Shi, SL Lin, J Kuebler, RC Schriver, NC
1438	Santanello, G Rochester, JB Porter, M Oster, DV Mehrotra, Z Li, EC King, ES Harpur, and
1439	DB Hall, 2009, Recommendations for Safety Planning, Data Collection, Evaluation and
1440	Reporting During Drug, Biologic and Vaccine Development: A Report of the Safety
1441	Planning, Evaluation, and Reporting Team (SPERT), Clin Trials, 6(5):430-440.
1442	
1443	Xia, HA, BJ Crowe, RC Schriver, M Oster, and DB Hall, 2011, Planning and Core Analyses
1444	for Periodic Aggregate Safety Data Reviews, Clin Trials, 8(2):175–182.
1445	
1446	Guidances for Industry:
1447	
1448	Guidance for clinical trial sponsors Establishment and Operation of Clinical Trial Data
1449	Monitoring Committees (March 2006)
1450	
1451	Guidance for industry Premarketing Risk Assessment (March 2005)
1452	
1453	For additional information on topics related to aggregate analysis, please refer to the following:
1454	
1455	Literature:
1456	
1457	Wittes, J, B Crowe, C Chuang-Stein, A Guettner, D Hall, Q Jiang, D Odenheimer, HA Xia,
1458	and J Kramer, 2015, The FDA's Final Rule on Expedited Safety Reporting: Statistical
1459	Considerations, Stat Biophar Res, 7(3):174–190.
1460	
1461	Guidance for Industry:
1462	
1463	Draft guidance for industry <i>Meta-Analyses of Randomized Controlled Clinical Trials to</i>
1464	Evaluate the Safety of Human Drugs or Biological Products (November 2018)


Draft — Not for Implementation

1466	For additional information on submitting IND safety reports in electronic format, please refer to
1467	the following:
1468	
1469	Guidances for Industry:
1470	·
1471	Draft guidance for industry Providing Regulatory Submissions in Electronic Format: IND
1472	Safety Reports (October 2019)
1473	
1474	Technical Conformance Guide <i>Electronic Submission of IND Safety Reports</i> (October 2019)
1475	

Draft — Not for Implementation

1476 APPENDIX A: FLOWCHART FOR DETERMINING WHETHER AN ADVERSE 1477 EVENT MEETS CRITERIA FOR IND SAFETY REPORTING TO FDA AND 1478 INVESTIGATORS

1479




Draft — Not for Implementation

1481 APPENDIX B: FLOWCHARTS FOR SUBMITTING SAFETY REPORTING FOR CONTROL DRUGS

1482

1483 Chart B.1: IND Sponsor is NOT the NDA or BLA Holder of the Control Drug


1484



Draft — Not for Implementation

1487 **APPENDIX B (continued):**

1488 Chart B.2: IND Sponsor IS also the NDA or BLA Holder of the Control Drug



Draft — Not for Implementation

1491 APPENDIX C: FLOWCHART FOR THE TWO APPROACHES TO AGGREGATE ANALYSES

